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Abstract
In the eld of biology, mathematical models are increasingly used to address biological
questions and the large data sets generated in experimental studies. Mathematical mod-
els traditionally are simplied and structured to be analytically tractable, but computing
power allows for more complex, larger models. Bayesian statistics lends itself naturally
to address parameter estimation problems in these large models. Bayesian statistical in-
ference is utilized in this thesis to obtain parameter estimates from a sparse data set on
populations in the HIV epidemic. Current estimates of the HIV epidemic indicate a de-
crease in the incidence of the disease in the undiagnosed subpopulation over the past 10
years. A lack of access to care, however, has not been considered when modeling the pop-
ulation. Populations at high risk for contracting HIV are twice as likely to lack access to
reliable medical care. In this thesis, we consider three contributors to the HIV population
dynamics: susceptible pool exhaustion, lack of access to care, and usage of anti-retroviral
therapy (ART) by diagnosed individuals. An extant problem in the mathematical study
of this system is deriving parameter estimates due to a portion of the population being
unobserved. We approach this problem by looking at the proportional change in the in-
fected subpopulations. We obtain estimates for the proportional change of the infected
subpopulations using hierarchical Bayesian statistics. The estimated proportional change
is used to derive epidemic parameter estimates for a system of stochastic dierential equa-
tions (SDEs). Model t is quantied to determine the best parametric explanation for
the observed dynamics in the infected subpopulations. Parameter estimates derived using
these methods provide interpretability and recovery of the system. Simulations suggest that
the undiagnosed population may be larger than currently estimated without signicantly
aecting the population dynamics.
iv
Chapter 1. Bayesian Statistics and Mathematical Biology
1.1. Mathematical modeling in biology
Advances in technology allow scientists to collect and analyze massive data sets. Uti-
lizing these data sets requires training in elds related to computer science, mathematics,
and statistics. The eld demands additional computational skills out of biologists, trending
away from the traditional paradigm of primarily experimental work. These trends create
a subset of modelers that are not quite traditional applied mathematicians, aren't statis-
ticians, and are mostly self-taught programmers. An existing challenge is providing this
growing population with the myriad of techniques available outside the training methods
available to them. The NSF's Directorate for Biological Sciences (BIO) found that the
unmet needs of its funded investigators centered around computational and mathematical
training [2]. The NSF recently began a 'Big Ideas' program to address problems that re-
quire long-term solutions, and not surprisingly this issue is in focus [1].
One area in particular where these resources have been lacking is Bayesian statis-
tics. A solution to this problem has been developing computational tools that are easy
to use [5, 6]. These tools perform Bayesian inference on SMBL (systems biology markup
language) models. SMBL models are procedurally generated, converting labeled wire dia-
grams of biological systems into models that can be simulated.
One issue facing widespread usage of these kinds of tools is that to seek them out, you
need to have some idea of the problems existing with the tools you currently use. Current
parameter estimation methods get the job done, and modelers may not be motivated to
look elsewhere, especially considering the hurdles to utilizing these methods - additional
programming, more computationally intensive, and a lack of background knowledge. How-
ever, obtaining estimates of parameter distributions instead of point estimates, or capturing
the variability of a system or stochasticity of a process motivate increasing the usage of
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Bayesian statistical inference in mathematical biology.
1.1.1. Approaches to modeling biological systems
Mathematical biology as a eld attempts to represent biological systems directly with
equations, while managing to simplify these systems to allow for mathematical or numeri-
cal analysis. The observed data D is a function of the response Y over time t. Normally
Y consists of a set of n observable and unobservable components, and the length of the
time under observation t is imposed based on nancial or temporal constraints, or prior
beliefs about the system behavior. Mathematical biologists try to construct Y so that it
directly represents the system in question. Two famous models that illustrate this is the
Lotka-Volterra model of population growth and the Michaelis-Menten model of enzyme
kinetics.
• Population modeling
The Lotka-Volterra model represents a system of predator and prey species. The ob-
jective of the model is to understand how predator and prey dynamics aect each other,
and this objective is used to simplify the model. We consider some birth rate of the prey
population α, and some death rate β as a result of the predator population. The natural
death rate of the prey is ignored for simplication purposes, as we assume that α is much
larger. Finally, we assume that the predator population can only grow at some rate δ ≤ β,
if prey are available as their primary or sole food source, and the predator die at some rate
ε. This provides the following equations:
dx
dt
= αx− βxy
dy
dt
= δxy − εy
2
This model contains many simplications of a very complex, large system with variability,
but it allows for biological inference on data of few observables. Most of the parameters
are not observable, but we can roughly count the number of prey or predators at a given
time to estimate the value of these rate constants; or predict the ability of a population to
survive predation when assuming some parameter values.
• Kinetics modeling
The Michaelis-Menten model of enzyme kinetics represents the following system:
E + S 
 ES → P + E
This system consist of an enzyme E combining with a substrate molecule S. These molecules
bind and separate at some rate kon and koff . When they exist in the ES conformation, the
product molecule P is formed at some rate kcat, and we assume that the enzyme separates
and is again able to bind to a substrate. We also assume that all these rates are constants,
and that we are looking at homogeneous populations of E, S, and P. In reality, some E, S,
P will have dierent parameters describing their behavior, and these features are time and
space dependent. A model based on this system is as follows.
dE
dt
= − konE · S + koffES + kcatES
dS
dt
= − konE · S + koffES
dES
dt
= konE · S − koffES − kcatES
dP
dt
= kcatES
The major contribution of Michaelis-Menten was not this system of equations, but
rather another simplication. They showed that for the majority of enzyme systems, it
appeared you could ignore the change in the ES population. This is because in general the
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amount of ES reaches some level pretty quickly, and if the number of S molecules present
is much larger than the number of E molecules, the change is not appreciable. Setting
dES
dt
= 0, the following model can be obtained:
ν =
dP
dt
=
VmaxS
KM + S
The value Vmax represents the maximum velocity observed in the production of P, and KM
refers to the amount of S required to achieve half of the maximum velocity.
• Dierent approaches to handle parameter problems
In both of these models, we simplify the system in an attempt to obtain a manage-
able equation that contains the observables. In the Lotka-Volterra model, we minimize
the number of unknown parameters since we can only get a rough estimate of the popu-
lation of predator or prey. In the Michaelis-Menten model, we formulate our equation to
be time-independent, containing two observables (Vmax and S) and one unknown parameter.
Historically, clever simplications and reductions have been applied to systems in or-
der to make them tractable. Parameter estimation and identiability in models with large
numbers of parameters is challenging and computationally intensive. Biological networks
can have disparate issues when it comes to available data. Some biological networks are
very dicult to observe, such as large populations; some networks are not observable, such
as what happens inside of a cell. These cases require special treatment to consider how
to estimate the parameters, and whether we can estimate them at all. Other biological
systems have large data sets associated with them. Bayesian statistical methods can be
used to address many of these existing issues.
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1.2. Bayesian statistics and parameter estimation
Bayes' rule describes the probability of event A occurring given event B occurred.
Pr(A|B) = Pr(B|A) Pr(A)
Pr(B)
The probability of A occurring given B occurred is equivalent to the probability of event B
occurring given A is occurred, multiplied by the probability of event A independent of event
B, divided by the probability of event B occurring independent of event A. In Bayesian
statistics, we take Pr(A) as the initial belief in the probability of A occurring. Parameter
estimation for biological models also considers the current evidence and a priori beliefs
about the system when constructing equations and considering parameters.
1.2.1. Handling big data
It has become relatively common place to collect data on the eect of experimental
conditions on the expression of the entire genome within a large population of cells. It
is also possible to use uorescent tagging of proteins or cellular components to track the
behavior of a large population of cells visually. One example of a Bayesian approach to
handling this type of data is the Naive Bayes classier [10]. The classier was used to
determine the log odds of dierent cellular markers in determining if a cell was likely to
die or to continue reproducing. The methodology allowed the researchers to avoid making
assumptions about the connections within this biological network, instead using Bayesian
statistics to determine the likely contributors to the cell's "decision" to reproduce or to die.
1.2.2. Parameter estimation for large biological networks
Traditional parameter estimation for dierential equation models consists of analyti-
cally solving equations for some initial conditions or knowns. This is not feasible for larger
nonlinear models. In this case various computational techniques are often used, such as
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least-squares tting or gradient descent. These methods involve setting initial parameter
estimates and parameter bounds, ideally based on previous experimental data.
A problem with this approach is that we are often more condent in some parameters
than in others. Bayesian parameter estimation techniques are an improvement on such
existing techniques by allowing the incorporation of parameter uncertainty [12].
The goal of biological mathematical modeling is normally not just producing accurate
simulations, but also generating new hypotheses. The proteins JAK2 and STAT5 form a
feedback loop that prevents treatment of some breast cancers [11]. A mathematical model
of this system has 29 components, 25 equations, and 113 parameters [9]. In total, 513
data points were available to analyze, obtained from 24 dierent experimental conditions,
making it a challenging problem to obtain parameter estimates. The authors used Markov
Chain Monte Carlo to obtain Bayesian inference on the parameters. The model then al-
lowed them to identify new observables in the system, generating new hypotheses.
1.2.3. Studying stochastic systems
Many biological systems may be better represented as stochastic systems, from the
biochemical level to the population level [7, 8]. Some non-Bayesian methods available to
study these systems include various stochastic simulation algorithms, like the Gillespie al-
gorithm. However, it is challenging to estimate parameters for stochastic models without
Bayesian statistics [12].
Bayesian methods for stochastic parameter estimates include using the stochastic na-
ture of the model to create a likelihood, to allow for Bayesian inference on these mod-
els. Approximate Bayesian computation (ABC) uses the dierence between the data and
stochastic simulations of the model to replace the likelihood. In the following chapter, we
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use Bayesian statistics to estimate two parameters that summarize the available information
on two HIV populations. Then we construct several stochastic dierential equation models
and numerically solve to obtain parameter estimates for these equations. We compare our
stochastic simulations of these models against the data, and quantify the goodness-of-t
by calculating the likelihood of observing the data given the model.
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Chapter 2. Estimating Epidemiological Parameters of a Stochastic
Dierential Model of HIV Dynamics Using a Hierarchical
Bayesian Model
2.1. Introduction
The human immunodeciency virus (HIV) progresses in three stages. The rst stage
lasts approximately 3 months and individuals in this stage are approximately 10 to 25 times
more eective at transmitting the disease [29]. The chronic stage can last from 5-10 years
without medication [38].This is followed by acquired immunodeciency syndrome (AIDS)
and death shortly thereafter [29]. Individuals with HIV may go many years without diag-
nosis, during which time they may expose uninfected individuals to HIV. Eorts to improve
the diagnosis rate include educational programs, as an individual's perceived risk was shown
to be highly correlated with the individual obtaining multiple HIV tests [19,22,24,35]. Sev-
eral studies have found a 50% reduction in risky behaviors after diagnosis, including safer
sex practices, reduction in partner number, and medications that reduce viral load [27,39].
Diagnosis events resulting in behavior modication are not thought to be sucient to erad-
icate the epidemic [20,27].
After diagnosis, infected individuals have the opportunity to take anti-retroviral ther-
apy (ART) that reduces their viral load and retards the progression of the disease. The
earlier that ART is received the higher the reduction in transmission events. ART therapies
could eradicate the epidemic in a population with high prevalence of infection even without
the additional eect of behavioral changes [20]. Mathematical models estimate that the
HIV epidemic could be reduced to less than 1% of the population infected (elimination
phase) with universal testing and by providing ART consistently to newly diagnosed in-
dividuals [36]. However, issues with adherence and resistance are well documented in the
This chapter was originally published as Renee Dale and BeiBei Guo "Estimating epidemiological
parameters of a stochastic dierential model of HIV dynamics using hierarchical Bayesian statistics."
PLOS ONE 2018 13(7): e0200126. The work is made available under the Creative Commons CC0 public
domain dedication. Published by PLOS.
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literature [1315, 25, 28, 32]. Patients tend to report their adherence as much higher than
it actually is, but studies indicate that even low adherence may be sucient for control
of the epidemic [13, 39]. Transmission is rare for individuals on ART, even with relatively
high plasma HIV concentrations [30, 33].
The largest barrier to eradication of the epidemic is lack of access to care, including
diagnostic services and ART costs or prescriptions. A lack in access to care could create
pockets of undiagnosed individuals while the overall trend appears to be a reduction in the
size of the epidemic [16]. Various studies report between 50 - 96% of diagnosed individuals
in the U.S. rely on public medical care to obtain their ART medications [18,21,32,34,39].
Access to care remains critical, but this has not been considered when modeling the dy-
namics of the epidemic [19,22].
Estimates using CD4 levels of newly diagnosed individuals suggest that the undiag-
nosed population is decreasing between 2005 - 2013 [37, 38]. CD4 levels can be used to
estimate the progression of HIV [40]. We consider three possible causes for this decrease
including exhaustion of the susceptible population. The size of the susceptible population
is not easy to estimate since it depends on behavior risk. High risk populations include
individuals in poverty and men who have sex with men (MSM) [38]. This is particularly
critical in the southern U.S., where individuals tend to be poor and lack access to medical
care [16,38]. As the at-risk population decreases the number of diagnoses will also decrease,
which will cause the estimated number of undiagnosed individuals to decrease.
An additional possibility is that the reduction in number of diagnoses is due to indi-
viduals lacking access to care. HIV is over-represented in impoverished populations where
access to diagnosis and treatment may be more dicult to obtain. In this case, the number
of newly diagnosed individuals is not representative of the number of undiagnosed individ-
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uals, and the estimates will be inaccurate. Finally, the usage of anti-retroviral therapies
reduces the viral load and transmission potential of infected individuals.
The diculty in studying this system mathematically lies in parameter estimates. A
minimal model of this system requires at least three parameters: transmission of the dis-
ease, diagnosis of the disease, and death due to the disease. Since knowledge about the
undiagnosed population is restricted to those who have been diagnosed, estimates of these
parameters are generally forced to assume that this population is representative of the
whole. Our motivation to model the system stochastically arises from heterogeneity due to
reporting delays associated with population-level data [31]. Stochastic modeling will allow
us to better understand both the eectiveness of our estimates and the quality of model
t.
In this work we use coupled statistical and mathematical methodology to study the
relationships between the three hypothesized causes and their respective population dy-
namics. We use hierarchical Bayesian statistics to get estimates for the size of the infected
populations and their proportional changes across the years. These estimates are used
to calculate epidemiological parameters for a system of stochastic dierential equations.
Currently we are not aware of any similar methods in the literature. Such a problem is
challenging as the proportional change across the populations is a hyperparameter control-
ling the yearly proportions, which each have their own statistical model. This results in a
large model that must be studied numerically.
The resulting simulations give insight into the implications of the estimated undiag-
nosed population on epidemiological parameters. Our model suggests that the undiagnosed
population may be larger than current estimates while recovering population dynamics.
The best recovery occurs when the increase in the diagnosed population due to diagnosis
10
is greater than the decrease in the undiagnosed population. We hope this study will help
inform future eorts to improve the situation of infected individuals and prevent future
outbreaks.
2.2. Materials and methods
2.2.1. Bayesian statistics
A Markov model where pt centered at qpt−1 is used to estimate the proportional change
in the infected populations over time, where pt is the proportion in the current year and q
is the proportional change. These random variables are estimated using Bayesian statistics.
The sampling model is xt ∼ Bin(nt, pt), where nt is population size in the current
year. The random variable q is taken as a hyperparameter for pt. The random variables to
be estimated for each infected subpopulation are q and pt, where t = 2005, ..., 2013. We
estimate the random variables of undiagnosed and diagnosed subpopulations independently.
• Prior
The prior for the proportional change q is a gamma distribution.
π(q) ∝ qα−1e−βq
The parameters were chosen so that the prior distribution was centered at the arith-
metic estimates of q obtained from the CDC [38]. The arithmetic estimates were obtained
by calculating:
1
n
Σni=2
pi
pi−1
The arithmetic estimate for the undiagnosed q (qu) is 0.979, and for the diagnosed q
(qd) 1.025. The priors used were GAM(9.79,10) and GAM(10.25,10) so they were centered
at 1.
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The prior for the random variable pt, the undiagnosed proportion, is a beta distribution
centered at the previous proportion times q. The parameters of the beta distribution are
α = 0.1nt−1 × qpt−1, and β = 0.1nt−1 − α.
π(pt) ∝ pα−1t (1− pt)β−1
In the case where t = 1, the previous undiagnosed proportion is taken to be the expert
opinion of 20%, and the diagnosed proportion to be 1−p0(undiagnosed) [23]. The prior for
the diagnosed population is formulated in the same way. Population sizes were considered
in units of thousands.
• Likelihood
The likelihood is a binomial distribution, representing the chance of selecting an un-
diagnosed or diagnosed individual at random from the total infected population. For a
given year t, the proportion of undiagnosed individuals depends on the total number of
individuals:
L(pt|xt, nt) ∝ pxtt (1− pt)nt−xt
where xt is the total number of undiagnosed or diagnosed individuals, and nt is the
total number of infected individuals. The likelihood across all the years is the product of
each year's likelihood.
L(p1, p2, ..., p9|x1, x2, ..., x9, n1, n2, ..., n9) ∝ Π9t=1pxtt (1− pt)nt−xt
The likelihood for the diagnosed population was formulated in the same way.
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• Posterior
The joint posterior distribution is proportional to the priors multiplied by the likeli-
hoods for all 9 years:
f(p1, p2, ..., p9, q) ∝ π(q)× Π9t=1π(pt|q, pt−1)× L(p1|xt=1)× L(p2|xt=2)× ...× L(p9|xt=9)
∝ qα−1e−βq × Π9t=1
(
pα−1t (1− pt)β−1 × pxtt (1− pt)nt−xt
)
The posterior full conditional of pt for t = 2005, ..., 2012 is:
f(pt|q, pt−1, pt+1) ∝ Π9t=1
(
L(pt|xt)× π(pt|q, pt−1)× π(pt+1|q, pt)
)
The posterior full conditional of 2013, the 9th year, is:
f(p9|x9, p8, q) ∝ L(p9|xt=9)× π(p9|q, p8)
The full conditional of q does not have a closed form. The forms of the diagnosed ran-
dom variables are the same. Random variable estimates were obtained using Metropolis-
Hastings nested within a Gibbs sampler over 100,000 iterations with R version 3.3.3 [41].
The proposal distribution was a truncated normal distribution, using package rmutil [42],
centered at the previous value of the parameter. Proportions 1 through 9 were sampled
consecutively, followed by hyperparameter q. The trace plots converged quickly, and the
rst 2000 samples were removed. Code is provided in Appendices B and C.
2.2.2. Stochastic dierential equations
The hyperparameter q was estimated to be 0.978 for the undiagnosed population and
1.036 for the diagnosed population. These were used as a boundary to solve for the epi-
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demiological parameters in a simple stochastic dierential model.
dU = (qu − 1)Udt+ dωtdt
dD = (qd − 1)Ddt+ dωtdt
where U is the undiagnosed and D is the diagnosed populations, and dωt ∼ Nor(0, σ)
is Brownian white noise with units
√
(t). The variance σ is chosen to be 10% of the size
of the population.
The simplest model is constructed describing the dynamics of the infected subpopula-
tions. The values of parameters transmission (τ), diagnosis (δ), and death (ε) are calculated
using the constraining q :
dU =
[
τ(U +D)− δU − ε
]
dt (2.1)
∼=(1− qu)Udt+ dωtdt (2.2)
=− 0.022Udt+ dωtdt (2.3)
dD =(δU − εD)dt (2.4)
∼=(1− qd)Ddt+ dωtdt (2.5)
=0.036Ddt+ dωtdt (2.6)
We consider the parameters pseudo-steady state, and use the 2005 population sizes to
estimate them. In addition, we assume that the general population are at steady state,
and consider only the increased death rate due to infection ε as 0.01 [38]. The diagnosis
rate δ is estimated by:
δU = qdD + εD =
0.046D2005
U2005
= 0.165
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and the transmission rate τ is estimated by:
τ(U +D) = (1− qu)U + δU + εU
τ =
0.153U2005
U2005 +D2005
= 0.0334
Due to the magnitude of the scale of this system we assume that all events will happen,
and the source of the stochasticity is primarily reporting issues. Tau leap algorithm was
used to preform the stochastic simulations. A time step of 1 year was selected, and the
population at time t+1 is the numerical solution of the population at time t and random
noise from a NOR(0,σ), where σ is 10% of the population at time t0 with units
√
t. The
initial conditions for the infected populations were sampled from the posterior distributions
obtained by the Bayesian estimates. Calculations were performed in Matlab [43] and code
is available upon request.
The diagnosis rate was calculated using data from [37]. The susceptible population is
estimated as twice the national average rate of self-identied MSM among adults. The
mortality rate increase due to HIV was estimated using data from [38]. All calculations,
including the eective parameter rates, are provided in Appendix A (in progress).
2.3. Results
2.3.1. Bayesian model
Bayesian estimates for the proportions of diagnosed or undiagnosed individuals was
obtained concurrently with the estimated proportional change. The prior distribution was
chosen to be a beta for the proportions and a gamma for the proportional changes. The
likelihood function was a binomial, representing the chance of randomly selecting a diag-
nosed or undiagnosed individual from a pool of infected individuals. The posterior did not
have a closed form. Due to the symmetry of the posterior samples we summarize them us-
ing their mean and variance. The posterior means of the proportions for both undiagnosed
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and diagnosed estimates are very close to the original data (Fig. 2.1) [37]. The posterior
mean of qu is 0.96, and qd is 1.02. This means that 96% of the undiagnosed population is
preserved from year to year, or is dropping by about 4% per year. Similarly, the diagnosed
population is increasing by 2% per year. Posterior means and variances are given in Table
2.1.
Table 2.1. Summary statistics of the posterior distribution. The parameter p represents
the estimated size of the proportion in that year. The hyperparameter q represents the
estimated proportional change of the population across all years.
Undiagnosed Diagnosed
Parameters Mean Variance Parameters Mean Variance
p2005 0.78 0.0006 p2005 0.22 0.0006
p2006 0.79 0.0011 p2006 0.21 0.0006
p2007 0.80 0.0012 p2007 0.20 0.0006
p2008 0.81 0.0012 p2008 0.16 0.0006
p2009 0.82 0.0012 p2009 0.19 0.0006
p2010 0.82 0.0012 p2010 0.18 0.0006
p2011 0.83 0.0012 p2011 0.18 0.0006
p2012 0.83 0.0012 p2012 0.17 0.0005
p2013 0.84 0.0012 p2013 0.16 0.0005
qd 1.036 0.1046 qu 0.978 0.0978
2.3.2. Stochastic dierential model
The Bayesian estimates of the proportional change in the diagnosed and undiagnosed
population from 2005 to 2013 were used to determine the epidemiological parameters for a
system of stochastic dierential equations. The parameters transmission (τ), diagnosis (δ),
and death (ε) were calculated using the proportional changes in the respective population.
dU = (qu − 1)Udt+ dωtdt =
[
τ(U +D)− δU − εU
]
dt (2.7)
dD = (qd − 1)Ddt+ dωtdt =
[
δU − εD
]
dt (2.8)
where U is the undiagnosed and D is the diagnosed populations, and dωt ∼ N(0, σ) is
the noise term. These base estimates t the data very well (Fig. 2.2).
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Figure 2.1. Posterior information obtained from hierarchical Bayesian statistics. Bayesian
estimates are shown as hollow squares with error bars showing standard deviations. Es-
timated proportion of diagnosed (pink) and undiagnosed (blue) populations recover the
estimated proportions (circles). Data obtained from [37].
• Exhaustion of susceptibles
In the case where the susceptible population is not much larger than the infected
population, the transmission is dependent on the size of both populations. We estimate
the susceptible population size as a fraction of the total infected population:
S = fT
Then this is substituted into the model. The transmission term becomes
τTS ∼= τfT 2
This gives an eective increase of fτ in the transmission rate - see Table 2.2. This
increase causes the simulations to fail to recover the diagnosed and undiagnosed popula-
17
Figure 2.2. Method Validation. The method was tested by simulating with the epidemio-
logical parameters calculated using the Bayesian estimates of the proportional changes as
constraints. The mean of 100 stochastic simulations (pink line) is compared with the data
(circles). Proportions are relative to initial proportion.
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tion dynamics, although the susceptible population does decrease signicantly (Fig. 2.3).
This result is intuitive since the infection rate is increased, but the diagnosis rate is not
representative of this rate.
• Lack of access to care
Lack of access to care may be conceptualized as pockets of undiagnosed individuals who
are not being diagnosed. To capture this, we consider the diagnosis rate to be independent
of the size of the undiagnosed population. The diagnosis rate is estimated as:
δU = qdD + εD =
0.046D2005
U2005
· U2005 = 0.036
The resulting equation for the undiagnosed subpopulation then becomes:
dU =
[
τ(U +D)− δ0 − εU
]
dt
where δ0 is 0.036. This large reduction in the diagnosis rate recovers the population
dynamics well (Fig. 2.4).
• ART usage
Since ART results in a viral load that has low chance of infecting a susceptible indi-
vidual, we removed these individuals from the pool of infected individuals able to transmit
the disease. Since 96% of diagnosed individuals reported taking anti-retroviral therapies in
a previous study, the transmission term was modied as follows [39].
τ
[
U + (1− 0.96)D
]
Variable or poor adherence on the part of diagnosed individuals is ignored due to the
body of literature indicating that large benet is gained from even poor adherence [13,25].
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Figure 2.3. Exhaustion of Susceptibles. Transmission of the disease is altered to reect the
impact of the size of the susceptible population. The mean of 100 stochastic simulations
(pink line) is compared to the data (circles). Proportions are relative to initial proportion.
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Figure 2.4. Lack of Access to Care. The eect of undiagnosed individuals lacking access
to care aects the rate of diagnosis of the undiagnosed individuals. The diagnosis rate is
held constant to reect this scenario. The mean of 100 stochastic simulations (pink line)
is compared with the data (circles). Proportions are relative to initial proportion.
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This gives good recovery of both subpopulation dynamics and agrees best with both undi-
agnosed and diagnosed estimates (Fig. 2.5).
2.3.3. Multiple causes
Since it seems likely that most or all of these scenarios aect the infected population
simultaneously, we analyze all their possible combinations (Appendix A). The parameters
were altered as described in Table 2.2. To determine the best cause, we quantify the good-
ness of t by determining the relative likelihood of observing the data given the mean and
variance of the stochastic simulations. These probabilities are given in Fig. 2.6 with nu-
merical details in the Appendix A table, as well as the average probability over the 9 years.
Table 2.2. Transmission and diagnosis rates are dierent under the dierent hypotheses.
Average likelihood across both populations and all years (Fig. 2.6, Supplemental Table in
Appendix A.
Model Transmission Rate Diagnosis Rate Likelihood
Base model τ(U +D) δU 0.83
Exhaustion of Susceptibles (ES) τf(U +D)2 δU 0.26
Lack of Access to Care (LAC) τ(U +D) δ0 0.88
Anti-retroviral Therapies (ART) τ(U + 0.04D) δU 0.75
ES and LAC τf(U +D)2 δ0 0.54
ES and ART τf(U + 0.04D)2 δU 0.52
LAC and ART τ(U + 0.04D) δ0 0.78
ES, LAC, and ART τf(U + 0.04D)2 δ0 0.58
Lack of access to care, ART usage, or their combined resulted in the best recovery of
the data for both the undiagnosed and diagnosed populations. Under the ART scenario,
the diagnosed population has been reduced by 96%, resulting in a dynamic reduction in
the transmission rate. We originally estimate the transmission rate to be 3.3% of the total
infected population. This is close to the literature estimate of around 4% [17, 23]. With
the majority of the diagnosed population removed, the eective transmission rate is much
lower. Under the LAC scenario, there is a constant diagnosis rate. This represents a yearly
reduction in the undiagnosed population and increase in the diagnosed population of 3.6%.
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Figure 2.5. Anti-retroviral Therapy Usage. To reect the high levels of ART prescription
and usage reported by diagnosed individuals this percentage is removed from the pool of
diagnosed individuals able to transmit the disease. The mean of 100 stochastic simulations
(pink line) is compared to the data (circles). Proportions are relative to initial proportion.
23
Figure 2.6. Model t was quantied by calculating the relative likelihood of observing the
data within the simulations. A higher likelihood is represented by a hotter color. From
left to right: Base model, Exhaustion of Susceptibles (ES), Lack of Access to Care (LAC),
Anti-Retroviral Therapy usage (ART), ES and LAC, ES and ART, LAC and ART, and
ES, LAC, and ART. Details provided in Appendix A.
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This means the diagnosed population grows faster than the undiagnosed population is re-
duced for a diagnosis event. Although lack of access to care in the undiagnosed population
would mean the data are inaccurate, in our case the best tting model is consistent for
both subpopulations.
2.4. Discussion
We were able to obtain conservative estimates of the proportional changes in the di-
agnosed and undiagnosed HIV-infected populations using hierarchical Bayesian statistics.
Our estimates suggest that the proportion of infected individuals who are undiagnosed is
decreasing by approximately 2.2% each year from 2005 to 2013, while the proportion of di-
agnosed individuals is increasing by approximately 3.6%. We used the proportional change
as constraints on a system of stochastic dierential equations. This allowed us to estimate
the transmission and diagnosis rates. We were able to recover reasonable parameter esti-
mates and population dynamics using this methodology. To learn more about the cause of
the decrease in the undiagnosed population, we considered some scenarios that would aect
the epidemiological parameters: exhaustion of the susceptible population, lack of access to
care, and reduction in viral load by anti-retroviral therapy.
We were able to recover the diagnosed population dynamics when we altered the param-
eters to reect these scenarios with the exception of including exhaustion of susceptibles.
Including the size of the susceptible population dramatically increased the transmission rate
and caused the size of the infected populations to increase rapidly. In the other scenarios
some interesting dynamics could be observed in the undiagnosed population. Lack of access
to care was simulated by considering diagnosis rate a constant unaected by the size of the
undiagnosed population. This resulted in an improvement in the likelihood of observing
the data (Fig. 2.6, Appendix A). Anti-retroviral therapy usage also improved the overall
recovery, but this eect was weaker for the undiagnosed population dynamics. Although
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the undiagnosed population size is dependent on the quality of the data available on the
diagnosed population of that year, these results indicate that the scenarios that maximizes
the probability of observing the diagnosed population also maximizes the probability of
observing the diagnosed population estimates.
The observed results suggest that lack of access to care and ART usage contribute to
the infected population dynamics. This is not unexpected. Many individuals with HIV are
reported to lack access to care [16, 26]. In areas with high poverty rates the death rate of
infected individuals is much higher than that of the general population [38,44]. In 2017 the
New York Times reported groups of untreated individuals in the deep south dying due to
their lack of access to care [16]. The eect of simulating a lack of access to care suggest this
to be a signicant contributing factor to the infected population dynamics. Both models
and studies have shown that providing ART to infected individuals in the early stages of
HIV reduces transmission events and frequency of death due to AIDS [20,28,30,32,33,36].
Even poor adherence may be enough to control or eradicate the epidemic and increase
quality of life for infected individuals [14, 15, 25]. Greater eort must be made to ensure
these populations have access to life-saving treatments.
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Appendix B. Diagnosed Population R Code
1 # # # # # # #
2 library(MCMCpack)
3 library(pracma)
4 library(msm)
5 library(rmutil)
6 # # # # # # DATA # # # # # #
7 # Source: Song R, Hall HI, Green TA, Szwarcwald CL, Pantazis N. Using CD4
Data to
8 #Estimate HIV Incidence, Prevalence, and Percent of Undiagnosed Infections
in
9 #the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes.
2017;74(1):3{9.
10 # # # # # # # # # # # # # # #
11
12 total = c(896.9,923.2,951.5,979.7,1006.5,1032.6,1057.8,1082.1,1104.6)
13 diagnosed=c(701.3758,729.328,760.2485,789.6382,818.2845,845.6994,871.6272,898.143,923.4456)
14 x=diagnosed
15
16 # # # # # # # # # # # # # # #
17
18 plot(total)
19 year=c(2005,2006,2007,2008,2009,2010,2011,2012,2013)
20 plot(year,undiagnosed,xlab=Year,ylab=,xaxt='n',yaxt='n')
21 axis(1,at=year,labels=year)
22 axis(2,at=undiagnosed,labels=undiagnosed)
23 title(main=Estimated Undiagnosed HIV Population)
24 plot(x)
25 v=matrix(0,8)
26 for (i in 1:8){v[i]=diagnosed[i+1]/diagnosed[i]}
27 mean(v)
28 var(v)
29
30 # # # # # #
31 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #
32 # # # # # #
33
34 p0=.8 #expert prior
35 n0=.25*total[1]
36
37 posteriorp=function(pt,pt1,pt.1,nt,nt1,nt.1,xt,xt1,xt.1,q,f){
38 ## this year t
39 talpha=pt.1*nt.1*f*q
29
40 tbeta=(1=pt.1*q)*nt.1*f
41
42 ## next year t+1
43 t1alpha=pt*nt*q*f
44 t1beta=(1=pt*q)*nt*f
45 # use beta to approximate binomial to keep numbers unrounded
46 a=dbeta(pt,talpha,tbeta)*dbeta(pt,xt+1,nt=xt+1)
47 b=dbeta(pt1,t1alpha,t1beta)*dbeta(pt1,xt1+1,nt1=xt1+1)
48 a*b
49 }
50
51 posterior_individ=function(pt,pt.1,xt,xt.1,nt,nt.1,q,f){
52 talpha=pt.1*nt.1*f*q; tbeta=(1=pt.1*q)*nt.1*f
53 dbeta(pt,xt+1,nt=xt+1)*dbeta(pt,talpha,tbeta)
54 }
55
56 posterior_q=function(pt,pt.1,xt,xt.1,nt,nt.1,q,f){
57 talpha=pt.1*nt.1*f*q; tbeta=(1=pt.1*q)*nt.1*f
58 dbeta(pt,talpha,tbeta)
59 }
60
61 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #
# # # # # # # # #
62 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #
# # # # # # # # #
63 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #
# # # # # # # # #
64
65 ##### GIBBS SAMPLER #####
66 sample=100000
67 gibb.sample=matrix(0,sample,10) #columns = parameters
68 tmu=matrix(.9,9,1) # initial values for proportion
69 q=1 # initial value for q
70 var_star = 0 # dummy variable for each iter
71
72 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #
# # # # # # # # #
73
74 sd.rw=matrix(.05,11);accept=matrix(0,11) # acceptance matrix
75 sd.rw[10]=.52
76 f=.1 # to scale the strength of the prior
77 for (i in 1:sample ){
78 set.seed(i) # for reproducibility
79 # # # # # # # # # # # # # # #
80 ## p1 : marginal posterior involves p0 and p1
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81 var_star <= rtnorm(1,tmu[1],sd.rw[1],0,1)
82 nom = posteriorp(var_star,tmu[2],p0,total[1],total[2],n0,x[1],x[2],0,q,f)
83 denom = posteriorp(tmu[1],tmu[2],p0,total[1],total[2],n0,x[1],x[2],0,q,f)
84 if (is.nan(nom)){ # error catch
85 nom=0;
86 }
87 if (nom == =Inf){ # error catch
88 nom = 0;
89 }
90 alpha <= min(1, nom/denom)
91 if (is.nan(alpha)){ # error catch
92 alpha=0
93 }
94 r <= runif(1,0,1)
95 if (r<=alpha ) {
96 accept[1] <= accept[1]+1
97 tmu[1] <= var_star # accept proposed value
98 }
99 gibb.sample[i,1]=var_star
100 # # # # # # # # # # # # # # #
101 ## p2 = p8 : marginal posteriors involve previous, current, and next p's
102 for (j in 2 : 8){
103 var_star <= rtnorm(1,tmu[j],sd.rw[j],0,1)
104 nom =
posteriorp(var_star,tmu[j+1],tmu[j=1],total[j],total[j+1],total[j=1],x[j],x[j+1],0,q,f)
105 denom =
posteriorp(tmu[j],tmu[j+1],tmu[j=1],total[j],total[j+1],total[j=1],x[j],x[j+1],0,q,f)
106 if (is.nan(nom)){
107 nom=0;
108 }
109 if (nom == =Inf){
110 nom = 0;
111 }
112 alpha <= min(1, nom/denom)
113 if (is.nan(alpha)){
114 alpha=0
115 }
116 r <= runif(1,0,1)
117 if (r<=alpha ) {
118 accept[j] <= accept[j]+1
119 tmu[j] <= var_star
120 }
121 gibb.sample[i,j]=var_star
122 }
123 # # # # # # # # # # # # # # #
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124 ## p9 : marginal posterior involves only p8 and p9
125 var_star <= rtnorm(1,tmu[9],sd.rw[9],0,1)
126 nom = posterior_individ(var_star,tmu[8],x[9],x[8],total[9],total[8],q,f)
127 denom = posterior_individ(tmu[9],tmu[8],x[9],x[8],total[9],total[8],q,f)
128 if (is.nan(nom)){
129 nom=0;
130 }
131 if (nom == =Inf){
132 nom = 0;
133 }
134 alpha <= min(1, nom/denom)
135 if (is.nan(alpha)){
136 alpha=0
137 }
138 r <= runif(1,0,1)
139 if (r<=alpha ) {
140 accept[9] <= accept[9]+1
141 tmu[9] <= var_star
142 }
143 gibb.sample[i,9]=var_star
144 # # # # # # # # # # # # # # #
145 # q : marginal posterior involves all priors
146 var_star= rtnorm(1,q,sd.rw[10],0)
147 nom=dgamma(var_star,10.254,10)# prior centered @ one
148 denom=dgamma(q,10.254,10)
149 nom = nom*posterior_q(tmu[1],p0,x[1],0,total[1],n0,var_star,f)
150 denom = denom*posterior_q(tmu[1],p0,x[1],0,total[1],n0,q,f)
151 for (k in 2:9){
152 nom=nom*posterior_q(tmu[k],tmu[k=1],x[k],x[k=1],total[k],total[k=1],var_star,f)
153 denom=denom*posterior_q(tmu[k],tmu[k=1],x[k],x[k=1],total[k],total[k=1],q,f)
154 }
155 if (is.nan(nom)){
156 nom=0;
157 }
158 if (nom == =Inf){
159 nom = 0;
160 }
161 alpha <= min(1, nom/denom)
162 if (is.nan(alpha)){
163 alpha=0
164 }
165 r <= runif(1,0,1)
166 if (r<=alpha ) {
167 accept[10] <= accept[10]+1
168 q <= var_star
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169 }
170 gibb.sample[i,10]=var_star
171 }
172 accept/sample
173
174 burnin=2000
175 plot(gibb.sample[burnin:sample,1])
176 plot(gibb.sample[burnin:sample,2])
177 plot(gibb.sample[burnin:sample,3])
178 plot(gibb.sample[burnin:sample,4])
179 plot(gibb.sample[burnin:sample,5])
180 plot(gibb.sample[burnin:sample,6])
181 plot(gibb.sample[burnin:sample,7])
182 plot(gibb.sample[burnin:sample,8])
183 plot(gibb.sample[burnin:sample,9])
184 plot(gibb.sample[burnin:sample,10])
185
186 m1=mean(gibb.sample[burnin:sample,1])
187 m2=mean(gibb.sample[burnin:sample,2])
188 m3=mean(gibb.sample[burnin:sample,3])
189 m4=mean(gibb.sample[burnin:sample,4])
190 m5=mean(gibb.sample[burnin:sample,5])
191 m6=mean(gibb.sample[burnin:sample,6])
192 m7=mean(gibb.sample[burnin:sample,7])
193 m8=mean(gibb.sample[burnin:sample,8])
194 m9=mean(gibb.sample[burnin:sample,9])
195 m10=mean(gibb.sample[burnin:sample,10])
196
197 v1=var(gibb.sample[burnin:sample,1])
198 v2=var(gibb.sample[burnin:sample,2])
199 v3=var(gibb.sample[burnin:sample,3])
200 v4=var(gibb.sample[burnin:sample,4])
201 v5=var(gibb.sample[burnin:sample,5])
202 v6=var(gibb.sample[burnin:sample,6])
203 v7=var(gibb.sample[burnin:sample,7])
204 v8=var(gibb.sample[burnin:sample,8])
205 v9=var(gibb.sample[burnin:sample,9])
206 v10=var(gibb.sample[burnin:sample,10])
207
208 hist(gibb.sample[burnin:sample,10],ylim=c(0,1.75),prob=TRUE,xlab='',col=00a1c0,main=expression('Posterior
Histogram of q'[u]),cex=1)
209 hist(gibb.sample[burnin:sample,1],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2005')
210 hist(gibb.sample[burnin:sample,2],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2006')
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211 hist(gibb.sample[burnin:sample,3],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2007')
212 hist(gibb.sample[burnin:sample,4],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2008')
213 hist(gibb.sample[burnin:sample,5],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2009')
214 hist(gibb.sample[burnin:sample,6],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2010')
215 hist(gibb.sample[burnin:sample,7],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2011')
216 hist(gibb.sample[burnin:sample,8],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2012')
217 hist(gibb.sample[burnin:sample,9],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2013')
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Appendix C. Undiagnosed Population R Code
1
2 # # # # # # #
3 library(MCMCpack)
4 library(pracma)
5 library(msm)
6 library(rmutil)
7 # # # # # # DATA # # # # # #
8 total = c(896.9,923.2,951.5,979.7,1006.5,1032.6,1057.8,1082.1,1104.6)
9 undiagnosed = c(.218,.21,.201,.194,.187,.181,.176,.17,.164)
10 x=undiagnosed*total
11 plot(total)
12 plot(year,undiagnosed,xlab=Year,ylab=,xaxt='n',yaxt='n')
13 axis(1,at=year,labels=year)
14 axis(2,at=undiagnosed,labels=undiagnosed)
15 title(main=Estimated Undiagnosed HIV Population)
16 plot(x)
17 v=matrix(0,8)
18 for (i in 1:8){v[i]=undiagnosed[i+1]/undiagnosed[i]}
19 mean(v)
20 var(v)
21 # # # # # #
22 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #
23 # # # # # #
24
25 p0=.2 #expert prior = eqsual to proportion
26 n0=.25*total[1]
27
28 qs0=1 # assume no change:
29 beta0_qs=.5; alpha0_qs=2; #uninformative
30
31 qsprior=function(alpha,beta,q){
32 q^(alpha=1)*exp(=q/beta)
33 }
34
35 posteriorp=function(pt,pt1,pt.1,nt,nt1,nt.1,xt,xt1,xt.1,q,f){
36 ## this year t
37 talpha=pt.1*nt.1*f*q
38 tbeta=(1=pt.1*q)*nt.1*f
39
40 ## next year t+1
41 t1alpha=pt*nt*q*f
42 t1beta=(1=pt*q)*nt*f
35
43 a=dbeta(pt,talpha,tbeta)*dbeta(pt,xt+1,nt=xt+1)
44 b=dbeta(pt1,t1alpha,t1beta)*dbeta(pt1,xt1+1,nt1=xt1+1)
45 a*b
46 }
47
48 posterior_individ=function(pt,pt.1,xt,xt.1,nt,nt.1,q,f){
49 talpha=pt.1*nt.1*f*q; tbeta=(1=pt.1*q)*nt.1*f
50 dbeta(pt,xt+1,nt=xt+1)*dbeta(pt,talpha,tbeta)
51
52 }
53
54 posterior_q=function(pt,pt.1,xt,xt.1,nt,nt.1,q,f){
55 talpha=pt.1*nt.1*f*q; tbeta=(1=pt.1*q)*nt.1*f
56 dbeta(pt,talpha,tbeta)
57 }
58
59 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #
# # # # # # # # #
60 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #
# # # # # # # # #
61 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #
# # # # # # # # #
62
63 ##### GIBBS SAMPLER #####
64 sample=100000
65 gibb.sample=matrix(0,sample,11) #columns = parametrs; check for convergence
66 tmu=matrix(.2,9,1)
67 q=.9
68 var_star = 0 # dummy variable for each iter
69
70 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #
# # # # # # # # #
71
72 sd.rw=matrix(.05,11);accept=matrix(0,11)
73 sd.rw[10]=.3
74
75 f=.1
76 for (i in 1:sample ){
77 set.seed(i)
78 # # # # # # # # # # # # # # #
79 ## 1
80 var_star <= rtnorm(1,tmu[1],sd.rw[1],0,1)
81 nom = posteriorp(var_star,tmu[2],p0,total[1],total[2],n0,x[1],x[2],0,q,f)
82 denom = posteriorp(tmu[1],tmu[2],p0,total[1],total[2],n0,x[1],x[2],0,q,f)
83 if (is.nan(nom)){
36
84 nom=0;
85 }
86 if (nom == =Inf){
87 nom = 0;
88 }
89 alpha <= min(1, nom/denom)
90 if (is.nan(alpha)){
91 alpha=0
92 }
93 r <= runif(1,0,1)
94 if (r<=alpha ) {
95 accept[1] <= accept[1]+1
96 tmu[1] <= var_star
97 }
98 gibb.sample[i,1]=var_star
99 # # # # # # # # # # # # # # #
100 ## 2 = 8
101 for (j in 2 : 8){
102 var_star <= rtnorm(1,tmu[j],sd.rw[j],0,1)
103 nom =
posteriorp(var_star,tmu[j+1],tmu[j=1],total[j],total[j+1],total[j=1],x[j],x[j+1],0,q,f)
104 denom =
posteriorp(tmu[j],tmu[j+1],tmu[j=1],total[j],total[j+1],total[j=1],x[j],x[j+1],0,q,f)
105 if (is.nan(nom)){
106 nom=0;
107 }
108 if (nom == =Inf){
109 nom = 0;
110 }
111 alpha <= min(1, nom/denom)
112 if (is.nan(alpha)){
113 alpha=0
114 }
115 r <= runif(1,0,1)
116 if (r<=alpha ) {
117 accept[j] <= accept[j]+1
118 tmu[j] <= var_star
119 }
120 gibb.sample[i,j]=var_star
121
122 }
123 # # # # # # # # # # # # # # #
124 ## 9
125 var_star <= rtnorm(1,tmu[9],sd.rw[9],0,1)
126 nom = posterior_individ(var_star,tmu[8],x[9],x[8],total[9],total[8],q,f)
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127 denom = posterior_individ(tmu[9],tmu[8],x[9],x[8],total[9],total[8],q,f)
128 if (is.nan(nom)){
129 nom=0;
130 }
131 if (nom == =Inf){
132 nom = 0;
133 }
134 alpha <= min(1, nom/denom)
135 if (is.nan(alpha)){
136 alpha=0
137 }
138 r <= runif(1,0,1)
139 if (r<=alpha ) {
140 accept[9] <= accept[9]+1
141 tmu[9] <= var_star
142 # likelihood[i,9]=nom;
143 }
144 gibb.sample[i,9]=var_star
145 # # # # # # # # # # # # # # #
146 # q
147 var_star= rtnorm(1,q,sd.rw[10],0)
148 #upper= q+sd.rw[10]; lower = q=sd.rw[10]
149 #if (lower<0){lower=0}
150 #var_star= runif(1,lower,upper)
151 nom=dgamma(var_star,9.788,10)
152 denom=dgamma(q,9.788,10)
153 nom = nom*posterior_q(tmu[1],p0,x[1],0,total[1],n0,var_star,f)
154 denom = denom*posterior_q(tmu[1],p0,x[1],0,total[1],n0,q,f)
155 for (k in 2:9){
156 nom=nom*posterior_q(tmu[k],tmu[k=1],x[k],x[k=1],total[k],total[k=1],var_star,f)
157 denom=denom*posterior_q(tmu[k],tmu[k=1],x[k],x[k=1],total[k],total[k=1],q,f)
158 }
159 if (is.nan(nom)){
160 nom=0;
161 }
162 if (nom == =Inf){
163 nom = 0;
164 }
165 alpha <= min(1, nom/denom)
166 if (is.nan(alpha)){
167 alpha=0
168 }
169 r <= runif(1,0,1)
170 if (r<=alpha ) {
171 accept[10] <= accept[10]+1
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172 q <= var_star
173 }
174 gibb.sample[i,10]=var_star
175
176 }
177 accept/sample
178 mean(gibb.sample[burnin:sample,10])
179
180 burnin=2000
181 plot(gibb.sample[burnin:sample,1])
182 plot(gibb.sample[burnin:sample,2])
183 plot(gibb.sample[burnin:sample,3])
184 plot(gibb.sample[burnin:sample,4])
185 plot(gibb.sample[burnin:sample,5])
186 plot(gibb.sample[burnin:sample,6])
187 plot(gibb.sample[burnin:sample,7])
188 plot(gibb.sample[burnin:sample,8])
189 plot(gibb.sample[burnin:sample,9])
190 plot(gibb.sample[burnin:sample,10])
191 00FF00 55FF00 AAFF00 FFFF00
192 hist(gibb.sample[burnin:sample,10],ylim=c(0,1.75),prob=TRUE,xlab='',col=00a1c0,main=expression('Posterior
Histogram of q'[u]),cex=1)
193 curve(dgamma(x,9.79,10),xlim=c(0,10),lwd=6,col=b57786,add=TRUE,cex=.75)
194
195 hist(gibb.sample[burnin:sample,1],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2005')
196 hist(gibb.sample[burnin:sample,2],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2006')
197 hist(gibb.sample[burnin:sample,3],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2007')
198 hist(gibb.sample[burnin:sample,4],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2008')
199 hist(gibb.sample[burnin:sample,5],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2009')
200 hist(gibb.sample[burnin:sample,6],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2010')
201 hist(gibb.sample[burnin:sample,7],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2011')
202 hist(gibb.sample[burnin:sample,8],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2012')
203 hist(gibb.sample[burnin:sample,9],prob=TRUE,xlab='',main='Posterior
Histogram of P(Undiagnosed), 2013')
204
205 m1=mean(gibb.sample[burnin:sample,1])
206 m2=mean(gibb.sample[burnin:sample,2])
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207 m3=mean(gibb.sample[burnin:sample,3])
208 m4=mean(gibb.sample[burnin:sample,4])
209 m5=mean(gibb.sample[burnin:sample,5])
210 m6=mean(gibb.sample[burnin:sample,6])
211 m7=mean(gibb.sample[burnin:sample,7])
212 m8=mean(gibb.sample[burnin:sample,8])
213 m9=mean(gibb.sample[burnin:sample,9])
214 m10=mean(gibb.sample[burnin:sample,10])
215 means2=c(m1,m2,m3,m4,m5,m6,m7,m8,m9)
216 y=c(1,2,3,4,5,6,7,8,9);year=c(2005,2006,2007,2008,2009,2010,2011,2012,2013)
217 plot(year,means2,xlab='',ylab='',ylim=c(.1,.25),type=p,pch=21,cex=2,col=red)
218 boxplot(gibb.sample[burnin:sample,1:9],xlab='',ylab='',xaxt='n')
219 lines(year,undiagnosed,type=p,pch=22,cex=2,col=blue)
220 axis(1,at=1:9,labels=year)
221 arrows(year,
means2=stdevs,year,means2+stdevs,length=0.05,angle=90,code=3,col=red)
222 axis(2,at=means2,labels=means2)
223 legend(2005,.155,c('Estimate','Observed'),pch =
c(21,22),col=c('red','blue'))
224 title(main=Posterior Estimates of Undiagnosed Proportion)
225
226 plot(year,means2,xlab='',ylab='',ylim=c(.1,.25),type=p,pch=21,cex=2,col=red)
227 lines(year,undiagnosed,type=p,pch=22,cex=2,col=blue)
228 arrows(year,
means2=stdevs,year,means2+stdevs,length=0.05,angle=90,code=3,col=red)
229 legend(2005,.155,c('Estimate','Observed'),pch =
c(21,22),col=c('red','blue'))
230 title(main=Posterior Estimates of Undiagnosed Proportion)
231
232
233 v1=var(gibb.sample[burnin:sample,1])
234 v2=var(gibb.sample[burnin:sample,2])
235 v3=var(gibb.sample[burnin:sample,3])
236 v4=var(gibb.sample[burnin:sample,4])
237 v5=var(gibb.sample[burnin:sample,5])
238 v6=var(gibb.sample[burnin:sample,6])
239 v7=var(gibb.sample[burnin:sample,7])
240 v8=var(gibb.sample[burnin:sample,8])
241 v9=var(gibb.sample[burnin:sample,9])
242 v10=var(gibb.sample[burnin:sample,10])
243 plot(vars/n)
244 plot(c(v1,v2,v3,v4,v5,v6,v7,v8,v9))
245 vars=c(v1,v2,v3,v4,v5,v6,v7,v8,v9)
246 stdevs=sqrt(vars)
247 arrows(year, means2=stdevs,year,means2+stdevs,length=0.05,angle=90,code=3)
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248
249 quantile((gibb.sample[burnin:sample,1]),c(.05,.95))
250 quantile((gibb.sample[burnin:sample,2]),c(.05,.95))
251 quantile((gibb.sample[burnin:sample,3]),c(.05,.95))
252 quantile((gibb.sample[burnin:sample,4]),c(.05,.95))
253 quantile((gibb.sample[burnin:sample,5]),c(.05,.95))
254 quantile((gibb.sample[burnin:sample,6]),c(.05,.95))
255 quantile((gibb.sample[burnin:sample,7]),c(.05,.95))
256 quantile((gibb.sample[burnin:sample,8]),c(.05,.95))
257 quantile((gibb.sample[burnin:sample,9]),c(.05,.95))
258 quantile((gibb.sample[burnin:sample,10]),c(.05,.95))
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